GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...
Company
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development
China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology
Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series...
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...